Arecor Therapeutics PLC (GB:AREC) has released an update.
Arecor Therapeutics PLC has announced successful Phase I trial results for AT278, its ultra-concentrated, ultra-rapid acting insulin, showing superiority over existing products for overweight and obese Type 2 diabetes patients. The innovative insulin formulation promises to improve mealtime glucose control with lower injection volumes, potentially revolutionizing insulin pump technology and offering a new option for those with high daily insulin needs. As the company prepares for further development, AT278 stands poised to disrupt the diabetes management market by enabling smaller, longer-wearing insulin pumps.
For further insights into GB:AREC stock, check out TipRanks’ Stock Analysis page.
